NASDAQ: KALVKalvista Pharmaceuticals Inc Stock
$8.97+0.00 (+0%)
Updated Dec 7, 2023
KALV Price
$8.97
Fair Value Price
$10.61
Market Cap
$309.99M
52 Week Low
$5.08
52 Week High
$11.45
P/E
-2.95x
P/B
2.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$100.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$78M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KALV Overview
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KALV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KALV ($8.97) is undervalued by 15.44% relative to our estimate of its Fair Value price of $10.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KALV ($8.97) is not significantly undervalued (15.44%) relative to our estimate of its Fair Value price of $10.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KALV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KALV due diligence checks available for Premium users.
Be the first to know about important KALV news, forecast changes, insider trades & much more!
KALV News
Valuation
KALV fair value
Fair Value of KALV stock based on Discounted Cash Flow (DCF)
Price
$8.97
Fair Value
$10.61
Undervalued by
15.44%
KALV ($8.97) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KALV ($8.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KALV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KALV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.95x
Industry
11.53x
Market
31.17x
KALV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.71x
Industry
5.45x
KALV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KALV's financial health
Profit margin
Revenue
$0.0
Net Income
-$27.7M
Profit Margin
0%
KALV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$138.7M
Liabilities
$24.3M
Debt to equity
0.21
KALV's short-term assets ($128.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KALV's short-term assets ($128.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KALV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KALV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.8M
Investing
$28.6M
Financing
$128.0k
KALV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KALV vs Biotech Stocks
Kalvista Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.